PURPOSE: Previous mouse studies suggesting that low fat diets slow prostate cancer growth often used corn oil (omega-6), which enhances prostate cancer growth, as the primary fat. Using a saturated fat based diet we previously found no significant difference in tumor growth between low and high fat fed SCID mice (Taconic Farms, Hudson, New York) xenografted with LAPC-4 cells. Whether similar results would hold in a castration model is unclear. MATERIALS AND METHODS: A total of 80 male SCID mice were fed a Western diet (40% fat and 44% carbohydrate) and injected with LAPC-4 human prostate cancer cells. When tumors were 200 mm(3), the mice were castrated and randomized to an isocaloric Western or a low fat diet (12% fat and 72% carbohydrate). Animals were sacrificed when tumors were 1,000 mm(3). Serum was collected and assayed for prostate specific antigen, insulin, insulin-like growth factor 1 and insulin-like growth factor binding protein 3. Tumors were assayed for total and phosphorylated Akt. RESULTS: Mouse weight was equivalent in the 2 groups. Overall dietary group was not significantly associated with survival (log rank p = 0.32). There were no statistically significant differences in prostate specific antigen (p = 0.53), insulin-like growth factor axis parameters (each p >0.05) or p-Akt-to-t-Akt ratios (p = 0.22) between the groups at sacrifice. CONCLUSIONS: In this xenograft model we found no difference in tumor growth or survival between low fat vs Western fed mice when the fat source was saturated fat. These results conflict with those of other studies in which corn oil was used to show that low fat diets delay prostate cancer growth, suggesting that fat type may be as important as fat amount in the prostate cancer setting. Copyright (c) 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
PURPOSE: Previous mouse studies suggesting that low fat diets slow prostate cancer growth often used corn oil (omega-6), which enhances prostate cancer growth, as the primary fat. Using a saturated fat based diet we previously found no significant difference in tumor growth between low and high fat fed SCIDmice (Taconic Farms, Hudson, New York) xenografted with LAPC-4 cells. Whether similar results would hold in a castration model is unclear. MATERIALS AND METHODS: A total of 80 male SCIDmice were fed a Western diet (40% fat and 44% carbohydrate) and injected with LAPC-4humanprostate cancer cells. When tumors were 200 mm(3), the mice were castrated and randomized to an isocaloric Western or a low fat diet (12% fat and 72% carbohydrate). Animals were sacrificed when tumors were 1,000 mm(3). Serum was collected and assayed for prostate specific antigen, insulin, insulin-like growth factor 1 and insulin-like growth factor binding protein 3. Tumors were assayed for total and phosphorylated Akt. RESULTS:Mouse weight was equivalent in the 2 groups. Overall dietary group was not significantly associated with survival (log rank p = 0.32). There were no statistically significant differences in prostate specific antigen (p = 0.53), insulin-like growth factor axis parameters (each p >0.05) or p-Akt-to-t-Akt ratios (p = 0.22) between the groups at sacrifice. CONCLUSIONS: In this xenograft model we found no difference in tumor growth or survival between low fat vs Western fed mice when the fat source was saturated fat. These results conflict with those of other studies in which corn oil was used to show that low fat diets delay prostate cancer growth, suggesting that fat type may be as important as fat amount in the prostate cancer setting. Copyright (c) 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Authors: R Yoshimura; H Sano; C Masuda; M Kawamura; Y Tsubouchi; J Chargui; N Yoshimura; T Hla; S Wada Journal: Cancer Date: 2000-08-01 Impact factor: 6.860
Authors: Tung H Ngo; R James Barnard; Todd Anton; Chris Tran; David Elashoff; David Heber; Stephen J Freedland; William J Aronson Journal: Cancer Res Date: 2004-02-15 Impact factor: 12.701
Authors: Tung H Ngo; R James Barnard; Pinchas Cohen; Stephen Freedland; Chris Tran; Frank deGregorio; Yahya I Elshimali; David Heber; William J Aronson Journal: Clin Cancer Res Date: 2003-07 Impact factor: 12.531
Authors: John C Mavropoulos; W Cooper Buschemeyer; Alok K Tewari; Dmitriy Rokhfeld; Michael Pollak; Yunhua Zhao; Phillip G Febbo; Pinchas Cohen; David Hwang; Gayathri Devi; Wendy Demark-Wahnefried; Eric C Westman; Bercedis L Peterson; Salvatore V Pizzo; Stephen J Freedland Journal: Cancer Prev Res (Phila) Date: 2009-05-26
Authors: Cristian P Moiola; Paola De Luca; Florencia Zalazar; Javier Cotignola; Santiago A Rodríguez-Seguí; Kevin Gardner; Roberto Meiss; Pablo Vallecorsa; Omar Pignataro; Osvaldo Mazza; Elba S Vazquez; Adriana De Siervi Journal: Clin Cancer Res Date: 2014-05-19 Impact factor: 12.531
Authors: Jorge Caso; Elizabeth M Masko; Jean A Thomas Ii; Susan H Poulton; Mark Dewhirst; Salvatore V Pizzo; Stephen J Freedland Journal: Prostate Date: 2012-10-04 Impact factor: 4.104
Authors: Luigi Fontana; Remi M Adelaiye; Antonella L Rastelli; Kiersten Marie Miles; Eric Ciamporcero; Valter D Longo; Holly Nguyen; Robert Vessella; Roberto Pili Journal: Oncotarget Date: 2013-12
Authors: J C Lloyd; E M Masko; C Wu; M M Keenan; D M Pilla; W J Aronson; J-Ta Chi; S J Freedland Journal: Prostate Cancer Prostatic Dis Date: 2013-07-23 Impact factor: 5.554